We are excited to present AB Science, Paris (OTC: ABSCF).
Full DD Report for ABSCF
Recent News from (OTC: ABSCF)
| 3 Things In Biotech You Should Learn Today: September 17, 2017|
|Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Pfizer ODAC meeting in earlier stage kidney cancer coming up! At the moment, Pfizer's (PFE)...|
| Date: September, 17 2017 08:00|
| Deciphera Pharmaceuticals Seeks $100 Million IPO|
|Quick Take Waltham, Massachusetts-based Deciphera Pharmaceuticals ( DCPH ), an anti-cancer drug company, intends to raise $100 million in gross proceeds from an IPO of its common stock. Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical firm that focuses on kinase inhibi...|
| Date: September, 07 2017 09:38|
| 3 Things In Biotech You Should Learn Today: May 14, 2017|
|Welcome to another edition of "3 Things in Biotech You Should Learn Today," a daily digest of news from the biotech world to help you come to grips with the wide world of scientific industry. Without further ado... Biogen's partner gets on track with gene therapy for retinitis pigmentosa ...|
| Date: May, 14 2017 06:00|
| Mitsubishi Bags ALS Approval Without Radical Benefit|
|Amyotrophic lateral sclerosis ((ALS)) patients will no doubt be relieved to have a new option after the FDA approved Mitsubishi Tanabe Pharma's edaravone, known in the US as Radicava. But with a $145,000-per-year price tag and no proof yet that it improves survival, getting it paid for might b...|
| Date: May, 09 2017 07:55|
| FDA approves first U.S. ALS treatment in 20 years|
|The FDA has approved the first treatment for amyotrophic lateral sclerosis -- "Lou Gehrig's disease" -- in more than two decades in the U.S. More news on: Mitsubishi Tanabe Pharma Corp. ADR, AB Science, Paris, Cytokinetics, Incorporated, Healthcare stocks news, Read more ... |
| Date: May, 05 2017 17:32|
| Collaborative Leukemia Trial Orbits Moonshot Initiative|
|The once-neglected blood cancer acute myeloid leukemia has seen a flurry of activity of late – which might explain why four companies with mid-stage projects are taking the unusual step of getting involved in a collaborative study. The Beat AML trial, led by the US Leukemia & Ly...|
| Date: October, 20 2016 13:53|
| AB Science Claims A Positive Result In Masitinib ALS Study|
|France’s AB Science (ABSCF) seems to have notched up an unexpected positive interim readout in a phase III study with its c-KIT inhibitor, masitinib, in the difficult indication of amyotrophic lateral sclerosis (ALS). The result could represent the first progress in the ALS field in mor...|
| Date: April, 19 2016 14:07|
Last 5 Days Trading Activity
Last 5 Days Short Activity
* Short Mode
Short Analysis provided by Squeeze Report.
About AB Science, Paris (OTC: ABSCF)
AB Science was founded in by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science.
- Alain Moussy / CEO, Founder
- ngineer ENSTA , and MBA Wharton. Former strategic consultant at Booz, Allen amp Hamilton and former head of Corporate Development at Carrefour. President of AFIRMM, association of mastocytosis patients.
Current Share Structure
- Market Cap: $379,333,185 - 03/16/2018
- Issue and Outstanding: 31,349,850 - 07/14/2011
Daily Technical Chart for (OTC: ABSCF)
Stay tuned for daily updates and more on (OTC: ABSCF)
It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter
More to come on (OTC: ABSCF)
Do your DD and if you choose, be ready to go!
The Research: All source information contained in this email is from the public sources mentioned below.
The Subway Trader
Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABSCF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of ABSCF and does not buy, sell, or trade any shares of ABSCF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/